Diagnosed cases of sepsis exceed 18 million a year with 1,400 patients dying daily in the developed world. Rapid treatment is critical to a patient’s recovery and therefore the time taken to diagnose sepsis is key.

This new technique is not dependent upon needing the symptoms of sepsis to be clinically displayed. Instead, a set of biomarkers are used in suspected patients to diagnose the presence of sepsis before the symptoms appear.

This allows the identification of sepsis in a patient much earlier, extending the treatment window and making it more effective.

Benefits

iTherapeutic window extended and mortality rates reduced
iCost of treatment lowered
iCan discriminate between sepsis, SIRS, and negative controls
iCompatible with RT-qPCR formats for rapid results

Also see

Properties

Project number

P1628

Patent status

GB grant (2527164)
EP application (15701566.0)

Commercial rights

Sole Rights / Non-exclusive

Source

Dstl

Regions

Worldwide

Available to license

Yes

Sectors

Medical

Download datasheet

For more details, including discrimination rates between sepsis and SIRS, please enter your email address below to access the datasheet.

Download

For more information about licensing this technology, or to speak to us about our other defence and security related intellectual property, please contact us.